GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Cash Ratio

Biomics Biopharma (ASX:BBM) Cash Ratio : 0.00 (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Biomics Biopharma's Cash Ratio for the quarter that ended in . 20 was 0.00.

Biomics Biopharma has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Biomics Biopharma's Cash Ratio or its related term are showing as below:

ASX:BBM's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.94
* Ranked among companies with meaningful Cash Ratio only.

Biomics Biopharma Cash Ratio Historical Data

The historical data trend for Biomics Biopharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Cash Ratio Chart

Biomics Biopharma Annual Data
Trend
Cash Ratio

Biomics Biopharma Semi-Annual Data
Cash Ratio

Competitive Comparison of Biomics Biopharma's Cash Ratio

For the Biotechnology subindustry, Biomics Biopharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomics Biopharma's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Cash Ratio falls into.



Biomics Biopharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Biomics Biopharma's Cash Ratio for the fiscal year that ended in . 20 is calculated as:

Biomics Biopharma's Cash Ratio for the quarter that ended in . 20 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomics Biopharma  (ASX:BBM) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Biomics Biopharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomics Biopharma (ASX:BBM) Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines